9-(Dihalobenzyl)adenines are prepared uncontaminated with other positional isomers in a series of mild transformations starting from 4,5,6-triaminopyrimidine and proceeding via 7-(N-formyl-N-dihalobenzyl)amino[1,2,5]-thiadiazolo[3,4-d]pyrimidine. The resulting compounds have anticoccidial activity and are useful in controlling cecal and/or intestinal coccidiosis when administered in minor quantities to animals, in particular to poultry usually in admixture with animal sustenance.

Patent
   RE31429
Priority
Oct 23 1979
Filed
Oct 23 1979
Issued
Oct 25 1983
Expiry
Oct 25 2000
Assg.orig
Entity
unknown
11
4
EXPIRED
1. The process for the preparation of compounds having the structure: ##STR10## wherein X1 and X2 are independently halogen by reacting the compound having the structure: ##STR11## wherein X1 and X2 are as defined above with Raney nickel in aqueous-alcohol solvent at about room temperature to about 125°C for a period of about 1 hour to 24 hours.
2. The compound 9-(2-chloro-6-fluorobenzyl)adenine free of 3-position isomers such that said compound has a melting point of 245°-246°C; a thin layer chromatogram on silica gel in chloroform-methanol (16:1) showing one spot with an Rf of 0.4; and a nuclear magnetic resonance spectrum in acetic acid-d4 of δ 5.70 (2 hydrogens-doublet), δ 7.35 (3 hydrogens-multiplet, and δ 8.15 (1 hydrogen-singlet).

This invention relates to a novel process for preparing 9-(2,6-dihalobenzyl)adenines. Said purines are described in U.S. Pat. No. 3,846,426 as being useful in the treatment and prevention of coccidoisis.

Coccidiosis is a widespread poultry disease which is produced by infections of protozoa of the genus Eimeria which causes severe pathology in the intestines and ceca of poultry. Some of the most significant of these species are E. tenella, E. acervulina, E. necatrix, E. brunetti and E. maxima. This disease is generally spread by the birds picking up the infectious organism in droppings on contaminated litter or ground, or by way of food drinking water. The disease is manifested by hemorrhage, accumulation of blood in the ceca, passage of blood in the droppings, weakness and digestive disturbances. The disease often terminates in the death of the animal, but the fowl which survive severe infections have had their market value substantially reduced as a result of the infection. Coccidiosis is, therefore, a disease of great economic importance and extensive work has been done to find new and improved methods for controlling and treating coccidial infections in poultry.

9-(dihalobenzyl)adenines have been prepared by alkylating adenine with dihalobenzyl halides. This process suffers from the disadvantage that alkylation is not selective and substitution occurs to some extent at the 3-position and other positions of adenine.

E. C. Taylor, et al., J. Org. Chem. 36, 3211 (1971) have reported that 9-substituted adenines (2) may be prepared via reductive cleavage and subsequent cyclization of 7-amidofurazano[3,4-d]pyrimidines (1). ##STR1## Although a wide variety of adenine derivatives was prepared, the authors were unable to effect the conversion of 5-unsubstituted 7-amidofurazano[3,4-d]pyrimidines (1, R═H, Y═O) to 2-unsubstituted adenines (2, R═H) due to the hydrolytic instability of the former compounds.

According to the process of the present invention this conversion has been successfully performed in the case wherein in compound (1) R═H, Y═S and R'═ dihalobenzyl to provide 9-(dihalobenzyl)adenines (2) wherein R═H and R'═ dihalobenzyl uncontaminated with positional isomers.

According to the process of the present invention 9-(dihalobenzyl)adenines, unsubstituted at the 2-position, are prepared without isomer contamination according to the process set forth in Table I.

TABLE I
______________________________________
##STR2##
##STR3##
##STR4##
##STR5##
##STR6##
##STR7##
______________________________________

wherein X1 and X2 are independently halogen.

4,5,6-Triaminopyrimidine (3), obtained by the process set forth in A. Shrage et al., J. Org. Chem., 16, 207 (1951), with thionyl chloride affords 7-amino[1,2,5]thiadiazolo[3,4-d]pyrimidine (4). Nucleophilic displacement of the 7-amino group of (4) by the process of Y. F. Shealy et al., J. Org. Chem., 27, 2135 (1964), at 100°C with 2,6-dihalobenzylamine (5) provides (6). Alternatively, (6) can be prepared from (4) by treatment of (4) with ammonia and 2,6-dihalobenzyl chloride in a sealed vessel at 100°C Formylation of (6) at room temperature with formic acetic anhydride yields (7) as a stable solid. Treatment of a solution of (7) with Raney nickel results in smooth desulfurization and formation of (9). The desulfurization may be carried out in an aqueous alcohol solvent wherein the alcohol preferably contains 1 to 6 carbon atoms. The reaction may be conducted at a temperature range of about room temperature to about 125°C for a period of about 1 hour to 24 hours. Preferred conditions are ethanol-water at about room temperature for about 2 hours.

The present process may be extended to prepare adenine derivatives having the following structure: ##STR8## wherein R and R' are independently H, alkyl, aryl or substituted aryl; and R" is alkyl or substituted benzyl. The substituents are those stable to Raney nickel reduction.

Included within the scope of the present invention are the intermediates useful for the preparation of anticoccidial agents having the structural formula: ##STR9## wherein X1 and X2 are independently halogen and R'" is H or CHO.

The following non-limiting Examples will serve to further illustrate the instant invention.

PAC Preparation of 7-Amino[1,2,5]thiadiazolo[3,4-d]pyrimidine

A flask was charged with 19.78 g. (0.15 mole) of 4,5,6-triaminopyrimidine and 163.0 g. (137 mole) of thionyl chloride and the mixture stirred at reflux for 18 hours. The dark orange reaction mixture was evaporated to dryness on the rotary evaporator and to the residue was added 500 ml. water and 40 ml. methanol. The resulting solution was adjusted to a pH of 7.5-8.0 with saturated sodium bicarbonate solution and heated to reflux. The hot mixture was filtered and the filtrate cooled to 0°-5°C in an ice-bath. The solid was collected by filtration, washed twice with 50 ml. ice water and twice with 50 ml. ether. The resulting tan product was dried in vacuo at 70°C overnight to afford 18.2 g. (79%) of product. M.p. 247°-249° C.; tlc on silica gel in chloroform-methanol (8:1) showed one spot at Rf ═0.4.

PAC Preparation of 2-Chloro-6-fluorobenzylamine

An autoclave was charged with 89.0 g. (0.5 mole) of 2-chloro-6-fluorobenzyl chloride, 170.0 g. (10 mole) ammonia and 50 ml. benzene. The reaction vessel was sealed and the contents heated at 100°C for 15 hours. The excess ammonia was carefully evaporated off from the cooled contents of the autoclave with a stream of nitrogen. The residue was washed with water, and the organic phase after drying with anhydrous MgSO4, fractionated to afford 72.4 g. (90%) of product as a clear liquid; b.p. 99°-100°C/20 mm; NMR (CDCl3) δ 1.46 (s, 2H); 3.88 (d, 2H); 7.00 (m, 3H).

PAC Preparation of 7-(2-Chloro-6-fluorobenzylamino)[1,2,5]thiadiazolo[3,4-d]pyrimidine

A flask was charged with 1.54 g. (0.01 mole) of 7-amino[1,2,5]thiadiazolo[3,4-d]pyrimidine prepared by the process set forth in Example 1 and 4.0 g. (0.025 mole) of 2-chloro-6-fluorobenzylamine prepared by the process set forth in Example 2. The suspension was stirred and heated at 105°C for 18 hours. Ten ml. water and 20 ml. hexane were added in one portion and the resulting solid collected by filtration. The cake was washed with hexane and dried at 50°C in vacuo to afford 2.86 g. (97%) of product. M.p. 224°-226°C; tlc on silica gel in chloroform-methanol (8:1) showed a single fluorescent blue spot at Rf ═0.8; NMR (DMSO-d6) δ 4.92 (2H, s); 7.21 (broad s, 3H); 8.44 (s, 1H); 9.45 (s, 1H).

Elemental analysis calculated for C11 H7 ClFN5 S: Calculated: C, 44.68; H, 2.38; N, 23.68. Found: C, 44.36; H, 2.38; N, 24.24.

PAC Preparation of 7-(2-Chloro-6-fluorobenzylamino)[1,2,5]thiadiazolo[3,4,-d]pyrimidine

An autoclave was charged with 1.54 g. (0.01 mole) of 7-amino[1,2,5]thiadiazolo[3,4-d]pyrimidine prepared by the process set forth in Example 1, 5.1 g. (0.3 mole) ammonia and 4.48 g. (0.025 mole) 2-chloro-6-fluorobenzyl chloride. The vessel was sealed and the contents heated at 110°C for 15 hours. After cooling and evaporation of the excess ammonia, the resulting solid was collected by filtration, washed successively with water and hexane to afford a 25% yield of product.

PAC Preparation of 7-(N-formyl-N-2-chloro-6-fluorobenzyl)amino[1,2,5]thiadiazolo[3,4-d]pyrimi dine

Formic acetic anhydride was prepared by stirring for 1 hour at 0°-5°C a solution of 18.4 g. (0.4 mole) of 98% formic acid and 40.8 g. (0.4 mole) acetic anhydride. Forty ml. of this solution was added to 2.0 g. (0.0067 mole) of 7-(2-chloro-6-fluorobenzylamino) [1,2,5]thiadiazolo[3,4-d]pyrimidine prepared by the process set forth in Example 3, and the solution stirred overnight. Any insoluble material was filtered off and the filtrate concentrated in vacuo at 50°C The solid residue was washed with ether and recrystallized from methanol to afford 2.0 g. (91%) of the desired compound. M.p. 133°-135° C.; tlc on silica gel in chloroform-methanol (16:1) showed one spot with Rf ═0.8; ir(CHCl3) 1730, 1540, 1120, 940 cm-1 ; NMR (DMSO-d6) δ 5.55 (s, 2H); 7.30 (broad s, 3H); 911 (s, 1H); 1033 (s, 1H).

PAC Preparation of 9-(2-Chloro-6-fluorobenzyl)adenine

A flask was charged with 0.5 g. (0.0016 mole) of 7-(N-formyl-N-2-chloro-6-fluorobenzyl)amino[1,2,5]thiadiazolo[3,4-d]pyrimi dine prepared by the process set forth in Example 5, 15 ml. ethanol, 15 ml. water and 7.0 g. of Raney nickel. The dark suspension was stirred at room temperature for 2 hours at which time tlc analysis showed the reaction to be complete. The reaction mixture was filtered through celite and the cake was washed with 200 ml. of boiling methanol. The clear filtrate was concentrated in vacuo to afford a while solid residue which was recrystallized from methanol-water to afford 0.18 g. (40%) of product. M.p. 245°-246°C; tlc on silica gel in chloroform-methanol (16:1) showed one spot with Rf ═0.4; NMR (acetic acid-d4) δ 5.70 (2H, d); 7.35 (3H, m); 8.15 (1H, s).

Elemental analysis calculated for C12 H9 ClFN5 : Calculated: C, 51.90; H, 3.27; N, 25.22; Cl, 12.77. Found: C, 51.77; H, 3.30; N, 25.43; Cl, 12.49.

Hartman, George D., Weinstock, Leonard M., Tull, deceased, Robert

Patent Priority Assignee Title
5110818, Oct 06 1988 Ciba-Geigy Corporation Anticonvulsive substituted-9-benzyl-9H-purines
5864037, Jun 06 1996 EURO-CELTIQUE, S A Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
5889014, Oct 12 1994 Euro-Celtique, S.A. Heterocyclic compounds for inhibiting phosphodiesterase IV
5922751, Jun 24 1994 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
5939422, Jun 22 1993 Euro-Celtique, S.A. Chemical compounds having PDE-IV inhibition activity
6075016, Apr 10 1996 EURO-CELTIQUE, S A 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
6166041, Apr 10 1997 EURO-CELTIQUE, S A 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
6228859, Dec 12 1997 EURO-CELTIQUE, S A Purine derivatives having phosphodiesterase IV inhibition activity
6294541, Jun 06 1996 Euro-Celtique S.A. Purine derivatives having phosphodiesterase IV inhibition activity
6310205, Jun 06 1996 Euro-Celtique, S.A. Hypoxathine compounds
6413975, Apr 02 1999 EURO-CELTIQUE, S A Purine derivatives having phosphodiesterase iv inhibition activity
Patent Priority Assignee Title
3813394,
3846426,
4100159, Feb 07 1977 Merck & Co., Inc. Process for preparation of 9-(2,6-dihalobenzyl)adenines
4171440, Oct 20 1977 Merck & Co., Inc. Process for purification of 9-(2,6-dihalobenzyl)adenines
/
Executed onAssignorAssigneeConveyanceFrameReelDoc
Oct 23 1979Merck & Co., Inc.(assignment on the face of the patent)
Date Maintenance Fee Events


Date Maintenance Schedule
Oct 25 19864 years fee payment window open
Apr 25 19876 months grace period start (w surcharge)
Oct 25 1987patent expiry (for year 4)
Oct 25 19892 years to revive unintentionally abandoned end. (for year 4)
Oct 25 19908 years fee payment window open
Apr 25 19916 months grace period start (w surcharge)
Oct 25 1991patent expiry (for year 8)
Oct 25 19932 years to revive unintentionally abandoned end. (for year 8)
Oct 25 199412 years fee payment window open
Apr 25 19956 months grace period start (w surcharge)
Oct 25 1995patent expiry (for year 12)
Oct 25 19972 years to revive unintentionally abandoned end. (for year 12)